Literature DB >> 2217783

Primary Ewing sarcoma: follow-up with Ga-67 scintigraphy.

D N Estes1, H L Magill, E I Thompson, F A Hayes.   

Abstract

While avid accumulation of gallium-67 citrate and technetium-99m methylene diphosphonate (MDP) occurs initially in most cases of primary Ewing sarcoma, uptake after therapy is less well defined. Thirty patients with Ewing sarcoma who underwent Ga-67 and bone scintigraphy at diagnosis, at completion of therapy, and at relapse from 1978 to 1988 were evaluated. All 30 patients showed less primary site Ga-67 activity following therapy. Twenty-three of 28 patients who underwent corresponding bone scintigraphy showed less uptake, but residual activity was usually more intense than with Ga-67. Avid reaccumulation of Ga-67 occurred in four of five patients with primary site relapse, while patients who underwent bone scintigraphy showed less change. It was concluded that a greater decrease in Ga-67 than in Tc-99m MDP uptake often occurs in patients successfully treated for primary Ewing sarcoma. Information obtained at Ga-67 scintigraphy is most likely to be helpful if results of bone scintigraphy remain abnormal or if occult relapse is suspected.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2217783     DOI: 10.1148/radiology.177.2.2217783

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Histopathologic and Radiologic Assessment of Chemotherapeutic Response in Ewing's Sarcoma: A Review.

Authors:  José M García-Castellano; Nagib Atallah Yordi; Carolina Reyes; John H Healey
Journal:  Sarcoma       Date:  2012-03-01

2.  Primary Ewing's Sarcoma of the Spine in a Two-Year-Old Boy.

Authors:  Ali J Electricwala; Jaffer T Electricwala
Journal:  Case Rep Orthop       Date:  2016-11-08

3.  Primary Ewing's sarcoma of the spine presenting as acute paraplegia.

Authors:  C V Gopalakrishnan; Adesh Shrivastava; H V Easwer; Suresh Nair
Journal:  J Pediatr Neurosci       Date:  2012-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.